세계의 췌장선암 치료 시장 보고서(2025년)

Pancreatic Adenocarcinoma Treatment Global Market Report 2025

US $ 4,490 ￦ 6,344,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,170,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,996,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

췌장선암 치료 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 표적 치료 및 면역 치료의 확대, 정밀 의학의 도입 증가, 바이오마커 기반 진단의 발전, 의료비 지출 증가, 새로운 치료법에 대한 임상 시험의 증가에 의해 주도될 수 있습니다. 주요 트렌드에는 AI 기반 신약 개발, 표적 약물 전달을 위한 나노 의학의 확대, 조기 발견을 위한 액체 생검의 도입, CRISPR 기반 유전자 치료의 발전, 치료 모니터링을 위한 원격 의료의 통합이 포함됩니다.

소화기계 암의 유병률 증가는 췌장선암 치료 시장의 성장을 견인할 것으로 예상됩니다. 이러한 암은 위, 간, 췌장, 장, 식도, 결장 등 소화에 관여하는 기관에서 발생합니다. 이러한 악성 종양의 발병률 증가는 주로 잘못된 식습관, 음주, 흡연과 같은 건강에 해로운 생활 방식에 기인합니다. 췌장선암 치료는 생존율을 높이고 환자의 삶의 질을 향상시키는 것을 목표로 소화기 계통에서 가장 공격적인 암 중 하나를 관리하는 데 중요한 역할을 합니다. 예를 들어, 2023년 1월 미국의 비영리 단체인 미국 암 협회(American Cancer Society)는 미국에서 6만 4,050명이 췌장암 진단을 받고 5만 550명이 췌장암으로 사망할 것으로 예상했습니다. 결과적으로 소화기계 암의 발병률 증가는 췌장선암 치료 시장의 확대에 기여하고 있습니다.

췌장선암 치료 시장을 선도하는 기업들은 치료 효과를 높이고 부작용을 최소화하며 종양 내성 문제를 해결하기 위해 이리노테칸 리포좀 주사와 같은 혁신적인 치료법 개발에 우선순위를 두고 있습니다. 이리노테칸 리포솜 주사는 리포솜에 캡슐화된 화학 치료 약물로, 췌장선암 치료에서 암세포로의 약물 전달을 개선하고 효과를 높이며 부작용을 줄이도록 설계되었습니다. 예를 들어, 2024년 2월 프랑스에 본사를 둔 바이오 제약 회사인 입센(Ipsen SA)은 미국 식품의약국(FDA)이 옥살리플라틴과 결합한 Onivyde(이리노테칸 리포좀 주사제)의 추가 신약 신청이 승인되었다고 발표했습니다. 이 병용 치료은 기존 치료에 비해 부작용을 최소화하면서 약물 전달을 개선하여 종양 표적을 강화합니다. 리포좀 제형은 이리노테칸의 생체 이용률과 지속 방출을 증가시키고, 옥살리플라틴은 췌장암 세포에 대한 추가적인 효능을 제공합니다. 이번 승인은 공격적인 암에 대한 보다 효과적인 치료 옵션에 대한 필요성을 충족시킬 수 있는 이 치료의 잠재력을 강조합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 췌장선암 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 췌장선암 치료 시장 : 성장률 분석
• 세계의 췌장선암 치료 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 췌장선암 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 췌장선암 치료 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 췌장선암 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 화학 치료
• 표적 치료
• 기타 치료
• 세계의 췌장선암 치료 시장 : 영향 부위별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 외분비
• 내분비
• 세계의 췌장선암 치료 시장 : 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 기타 채널
• 세계의 췌장선암 치료 시장 : 화학 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 단일 치료
• 병용 치료
• 세계의 췌장선암 치료 시장 : 표적 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 저분자 억제제
• 단일클론항체
• 세계의 췌장선암 치료 시장 : 기타 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 면역 치료
• 방사선 치료

제7장 지역별 및 국가별 분석

• 세계의 췌장선암 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 췌장선암 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 췌장선암 치료 시장 : 경쟁 구도
• 췌장선암 치료 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited(Japan)
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd
• Mylan NV
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Clovis Oncology Inc.
• Oncolytics Biotech, Inc.
• Zydus Cadila
• PharmaCyte Biotech Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 췌장선암 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 췌장선암 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 췌장선암 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Pancreatic adenocarcinoma treatment encompasses various medical strategies aimed at managing and combating pancreatic adenocarcinoma, the most common form of pancreatic cancer. Treatment approaches depend on factors such as cancer stage, tumor location, and patient health, typically involving a combination of surgery, chemotherapy, radiation therapy, and targeted therapies to enhance survival and quality of life.

The primary types of pancreatic adenocarcinoma treatment include chemotherapy, targeted therapy, and other modalities. Chemotherapy utilizes drugs to destroy or inhibit the growth of cancer cells and may be employed to shrink tumors before surgery, prevent recurrence post-surgery, or manage advanced stages by alleviating symptoms. The disease primarily affects the exocrine and endocrine regions of the pancreas. Treatment distribution occurs through various channels, including hospital pharmacies, retail pharmacies, and other healthcare providers.

The pancreatic adenocarcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides pancreatic adenocarcinoma treatment market statistics, including pancreatic adenocarcinoma treatment industry global market size, regional shares, competitors with a pancreatic adenocarcinoma treatment market share, detailed pancreatic adenocarcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic adenocarcinoma treatment industry. This pancreatic adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from $2.13 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth during the historic period can be attributed to the rising incidence of pancreatic cancer, advancements in chemotherapy and radiation therapy, increased awareness and early diagnosis, regulatory approvals of new treatments, and growing investment in oncology research.

The pancreatic adenocarcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth during the forecast period can be driven by the expansion of targeted and immunotherapy treatments, increasing adoption of precision medicine, advancements in biomarker-based diagnostics, rising healthcare expenditure, and a growing number of clinical trials for novel therapies. Major trends include the development of AI-driven drug discovery, expansion of nanomedicine for targeted drug delivery, adoption of liquid biopsy for early detection, advancements in CRISPR-based gene therapy, and the integration of telemedicine for treatment monitoring.

The rising prevalence of digestive system cancers is expected to drive the growth of the pancreatic adenocarcinoma treatment market. These cancers develop in organs involved in digestion, including the stomach, liver, pancreas, intestines, esophagus, and colon. The increasing incidence of such malignancies is largely attributed to unhealthy lifestyle choices such as poor diet, alcohol consumption, and smoking. Pancreatic adenocarcinoma treatment plays a vital role in managing one of the most aggressive cancers of the digestive system, with the goal of improving survival rates and enhancing patients' quality of life. For example, in January 2023, the American Cancer Society, a US-based non-profit organization, estimated that 64,050 individuals in the United States would be diagnosed with pancreatic cancer, while 50,550 were expected to succumb to the disease. As a result, the growing incidence of digestive system cancers is contributing to the expansion of the pancreatic adenocarcinoma treatment market.

Leading companies in the pancreatic adenocarcinoma treatment market are prioritizing the development of innovative therapies, such as irinotecan liposome injection, to enhance treatment efficacy, minimize side effects, and address tumor resistance challenges. Irinotecan liposome injection is a chemotherapy drug encapsulated in liposomes, designed to improve drug delivery to cancer cells, increase effectiveness, and reduce adverse effects in the treatment of pancreatic adenocarcinoma. For instance, in February 2024, Ipsen SA, a France-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application for Onivyde (irinotecan liposome injection) in combination with oxaliplatin. This combination enhances tumor targeting by improving drug delivery while minimizing side effects compared to conventional therapies. The liposomal formulation increases the bioavailability and sustained release of irinotecan, while oxaliplatin provides additional efficacy against pancreatic cancer cells. The approval highlights the regimen's potential to fulfill the need for more effective treatment options for this aggressive cancer.

In February 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela to expand its oncology pipeline by incorporating the clinical-stage assets of both companies, including SBP-101, which has shown promise in improving overall survival and response rates in metastatic pancreatic adenocarcinoma patients. This development aims to enhance treatment options for this highly aggressive cancer. Cancer Prevention Pharmaceuticals Inc. is a US-based biotechnology company specializing in innovative therapeutics designed to lower cancer risk and recurrence, with a particular focus on familial adenomatous polyposis (FAP), colorectal cancer prevention, and other rare diseases.

Major players in the pancreatic adenocarcinoma treatment market are Pfizer Inc., Roche AG, Merck & Co Inc., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited (Japan), Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen SA, Clovis Oncology Inc., Oncolytics Biotech Inc., Zydus Cadila, PharmaCyte Biotech Inc., and Infinity Pharmaceuticals Inc.

North America was the largest region in the pancreatic adenocarcinoma treatment market in 2024. The regions covered in pancreatic adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic adenocarcinoma treatment market includes revenues earned by entities by providing services such as chemotherapy administration, radiation therapy, surgical procedures, targeted therapy, immunotherapy, supportive care services, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic adenocarcinoma treatment market also includes sales of chemotherapeutic drugs, targeted therapy drugs, immunotherapy agents, radiation therapy equipment, surgical instruments, diagnostic tools, and supportive care medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Adenocarcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic adenocarcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic adenocarcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic adenocarcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Chemotherapy, Targeted Therapy, Other Types
• 2) By Affected Area: Exocrine, Endocrine
• 3) By Channel: Hospital Pharmacies, Retail Pharmacies, Other Channels
• Subsegments:
• 1) By Chemotherapy: Monotherapy; Combination Therapy
• 2) By Targeted Therapy: Small Molecule Inhibitors; Monoclonal Antibodies
• 3) By Other Types: Immunotherapy; Radiation Therapy
• Companies Mentioned:Pfizer Inc.; Roche AG; Merck & Co Inc.; Sanofi; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Adenocarcinoma Treatment Market Characteristics

3. Pancreatic Adenocarcinoma Treatment Market Trends And Strategies

4. Pancreatic Adenocarcinoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pancreatic Adenocarcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pancreatic Adenocarcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pancreatic Adenocarcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Pancreatic Adenocarcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pancreatic Adenocarcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pancreatic Adenocarcinoma Treatment Total Addressable Market (TAM)

6. Pancreatic Adenocarcinoma Treatment Market Segmentation

• 6.1. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Other Types
• 6.2. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine
• Endocrine
• 6.3. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Channels
• 6.4. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.5. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Inhibitors
• Monoclonal Antibodies
• 6.6. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Radiation Therapy

7. Pancreatic Adenocarcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Pancreatic Adenocarcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pancreatic Adenocarcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market

• 8.1. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pancreatic Adenocarcinoma Treatment Market

• 9.1. China Pancreatic Adenocarcinoma Treatment Market Overview
• 9.2. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pancreatic Adenocarcinoma Treatment Market

• 10.1. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pancreatic Adenocarcinoma Treatment Market

• 11.1. Japan Pancreatic Adenocarcinoma Treatment Market Overview
• 11.2. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pancreatic Adenocarcinoma Treatment Market

• 12.1. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pancreatic Adenocarcinoma Treatment Market

• 13.1. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pancreatic Adenocarcinoma Treatment Market

• 14.1. South Korea Pancreatic Adenocarcinoma Treatment Market Overview
• 14.2. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pancreatic Adenocarcinoma Treatment Market

• 15.1. Western Europe Pancreatic Adenocarcinoma Treatment Market Overview
• 15.2. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pancreatic Adenocarcinoma Treatment Market

• 16.1. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pancreatic Adenocarcinoma Treatment Market

• 17.1. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pancreatic Adenocarcinoma Treatment Market

• 18.1. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pancreatic Adenocarcinoma Treatment Market

• 19.1. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pancreatic Adenocarcinoma Treatment Market

• 20.1. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pancreatic Adenocarcinoma Treatment Market

• 21.1. Eastern Europe Pancreatic Adenocarcinoma Treatment Market Overview
• 21.2. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pancreatic Adenocarcinoma Treatment Market

• 22.1. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pancreatic Adenocarcinoma Treatment Market

• 23.1. North America Pancreatic Adenocarcinoma Treatment Market Overview
• 23.2. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pancreatic Adenocarcinoma Treatment Market

• 24.1. USA Pancreatic Adenocarcinoma Treatment Market Overview
• 24.2. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pancreatic Adenocarcinoma Treatment Market

• 25.1. Canada Pancreatic Adenocarcinoma Treatment Market Overview
• 25.2. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pancreatic Adenocarcinoma Treatment Market

• 26.1. South America Pancreatic Adenocarcinoma Treatment Market Overview
• 26.2. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pancreatic Adenocarcinoma Treatment Market

• 27.1. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pancreatic Adenocarcinoma Treatment Market

• 28.1. Middle East Pancreatic Adenocarcinoma Treatment Market Overview
• 28.2. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pancreatic Adenocarcinoma Treatment Market

• 29.1. Africa Pancreatic Adenocarcinoma Treatment Market Overview
• 29.2. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pancreatic Adenocarcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Pancreatic Adenocarcinoma Treatment Market Competitive Landscape
• 30.2. Pancreatic Adenocarcinoma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Pancreatic Adenocarcinoma Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited (Japan)
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Teva Pharmaceutical Industries Ltd
• 31.8. Mylan N.V.
• 31.9. Astellas Pharma Inc.
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Ipsen SA
• 31.12. Clovis Oncology Inc.
• 31.13. Oncolytics Biotech, Inc.
• 31.14. Zydus Cadila
• 31.15. PharmaCyte Biotech Inc.

32. Global Pancreatic Adenocarcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Adenocarcinoma Treatment Market

34. Recent Developments In The Pancreatic Adenocarcinoma Treatment Market

35. Pancreatic Adenocarcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Pancreatic Adenocarcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pancreatic Adenocarcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pancreatic Adenocarcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료